Remove Gene Expression Remove Genetics Remove Genome Remove Genomics
article thumbnail

Nucleome raises £37.5m to shine light on ‘dark genome’

pharmaphorum

million ($40 million) first-round financing that will be used to explore so-called ‘dark’ regions of the human genome. Nucleome’s platform adds 3D genomic information to a wealth of available genomic data, uncovering a new dimension of information that is disease as well as cell type-specific.

Genome 57
article thumbnail

Gene expression delivery tool ‘slides’ instructions into cells

Drug Discovery World

Researchers say they have successfully used a cell’s natural process for making proteins to ‘slide’ genetic instructions into a cell and produce critical proteins missing from those cells. . Two methods currently used to deliver protein-making packages into cells, ‘mini promoters’ and serotype-mediated gene expression, vary widely.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene Accessibility May Explain Why Alzheimer’s Gene, APOE4, is Less Dangerous for People of African Descent

Drug Discovery Today

Hussman Institute for Human Genomics at the University of Miami Miller School of Medicine have found that variations in chromatin accessibility, and thus gene expression, may explain why people of European descent with APOE4 gene variants have a greater risk of developing Alzheimer’s disease than people of African descent with similar genetics.

Gene 80
article thumbnail

Webinar: How to achieve high-throughput single-cell sequencing

Drug Discovery World

Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks.

Genome 52
article thumbnail

CRISPR screening: Achieving high-throughput single-cell sequencing

Drug Discovery World

Pooled CRISPR screens offer the ability to knock out or perturb many genes in a single experiment from several hundred to tens of thousands of targets in parallel. Genome-wide screens are becoming the standard for drug discovery to power unbiased identification of drug targets across gene regulatory networks.

Genome 52
article thumbnail

This week in drug discovery (2-6 October)  

Drug Discovery World

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52
article thumbnail

Moving the needle of CAR-T beyond oncology 

Drug Discovery World

DDW’s Megan Thomas speaks with Dr Blythe Sather, Vice President and Head of Research at Tune Therapeutics, about how genetic tuning will transform the reach for CAR-T therapies, the different diseases that can benefit, and the disruptive technology making this happen. MT: What is genetic tuning?